1. Clinical Overview of LC120

Formulation: L-Methionine 15 mg + Choline Chloride 50 mg + L-Carnitine 50 mg + Dexpanthenol (B5) 5 mg

Actions: Lipid oxidation, methylation cycle support, hepatic fat processing, mitochondrial energy (β-oxidation), Phase II detoxification, carbohydrate utilization, cholesterol transport.

Primary Use Cases: Weight-loss programs, metabolic support, lipid metabolism, methylation optimization, fatty acid oxidation, GLP-1 therapy adjunct, energy & exercise support.

Common co-administration: GLP-1 medications, thermogenic programs, nutritional plans, exercise prescription, hormone optimization therapy.

2. Mechanisms of Action

2.1 L-Methionine — Lipotropic & Methylation

Essential sulfur-containing amino acid: converts to SAMe supporting methylation, participates in fat metabolism/hepatic fat prevention, supports glutathione synthesis and detoxification.

2.2 Choline Chloride — Hepatic Fat Transport

Required for VLDL formation/hepatic fat export, fat/cholesterol metabolism, bile production, acetylcholine precursor. Deficiency leads to fatty liver and slowed metabolism.

2.3 L-Carnitine — Mitochondrial Fat Transport

Transports long-chain fatty acids into mitochondria, ATP production via β-oxidation, exercise recovery, increased metabolic rate.

2.4 Dexpanthenol (B5) — Coenzyme A & Adrenal Support

Coenzyme A production, fatty acid synthesis/breakdown, carbohydrate metabolism, adrenal hormone balance, metabolic stress recovery.

3. Evidence-Based Applications

3.1 Weight Management & Fat Oxidation

Improving fatty acid transport/oxidation, supporting caloric-deficit programs, enhancing GLP-1 therapy outcomes, reducing hepatic fat accumulation, improving metabolic flexibility.

3.2 Hepatic Health & Detoxification

Liver fat handling, Phase II detoxification, bile flow, hepatic steatosis prevention (adjunctive).

3.3 Exercise Performance & Recovery

L-Carnitine supports ATP production. Methionine + B5 improve methylation during exertion. Endurance and recovery enhancement.

3.4 GLP-1 Therapy Adjunct

May reduce GLP-1–related fatigue, support liver function, enhance fat-loss outcomes, reduce symptom burden in appetite-suppressed, slowed-gastric-emptying, and reduced-protein-intake patients.

3.5 Hormone Optimization Support

Useful with testosterone replacement, thyroid optimization, PCOS metabolic protocols.

4. Administration & Clinical Protocols

Routes: SC (preferred: abdomen, outer thigh, tricep) • IM (optional: deltoid, gluteal, vastus lateralis)
Dose: 1 mL SC or IM, 1–3×/week
Duration: 8–12 weeks, may continue longer
Standard Weight Loss: 1 mL SC once weekly
Enhanced Metabolic: 1 mL SC twice weekly
High-Performance / Athletes: 1 mL SC/IM three times weekly

5. Clinical Decision Trees

5.1 Patient Selection

Weight loss / fat oxidation goal? → LC120 appropriate

Fatigue or low energy? → Supportive (carnitine & B5)

Sluggish methylation / liver burden? → Beneficial (methionine + choline)

On GLP-1 therapy? → Recommended adjunct

Contraindications? → Modify or avoid

5.2 Frequency Selection

Sedentary / appetite suppression? → 1 mL weekly

Active / moderate exercise? → 1 mL twice weekly

Athlete / high-output / metabolic syndrome? → 1 mL three times weekly

6. Safety & Contraindications

6.1 Contraindications

6.2 Side Effects

Mostly mild: injection-site redness, mild GI upset (rare), temporary increased energy/warmth, fishy body odor from choline metabolism (uncommon).

6.3 Monitoring

Legal Disclaimer

This document is provided solely for educational and informational purposes. LC120 and comparable formulations consist of nutrients and/or peptides compounded for injectable use that are not FDA-approved for weight loss or metabolic treatment. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable. Use at your own risk.

References — LC120 Clinical Reference Guide

Methionine (L-Methionine)
1. Finkelstein, J. D. Methionine metabolism in mammals. J Nutr Biochem, 1(5), 228–237 (1990).
2. Lu, S. C. S-adenosylmethionine and hepatic methylation. FASEB J, 13(10), 1169–1183 (1999).
3. Brosnan, J. T., & Brosnan, M. E. The sulfur-containing amino acids. J Nutrition, 136(6), 1636S–1640S (2006).
4. Zeisel, S. H. Methionine and methyl-donor interactions in lipid metabolism. Nutrition Reviews, 70(9), 586–598 (2012).
Choline Chloride
5. Zeisel, S. H., & da Costa, K.-A. Choline: An essential nutrient. Nutrition Reviews, 67(11), 615–623 (2009).
6. Buchman, A. L., et al. Choline deficiency induces hepatic steatosis. Am J Clin Nutr, 70(3), 421–425 (1999).
7. Fischer, L. M., et al. Sex and genetic factors determine choline necessity. PNAS, 105(50), 19745–19750 (2008).
8. Zeisel, S. H. Choline, VLDL formation, hepatic lipid export. J Nutrition, 142(6), 1113–1117 (2012).
L-Carnitine
9. Bremer, J. Carnitine—metabolism and functions. Physiol Rev, 63(4), 1420–1480 (1983).
10. Rebouche, C. J. Carnitine function in human nutrition. J Am Coll Nutr, 21(2), 159–166 (2002).
11. Wall, B. T., et al. Dietary carnitine and fatty acid oxidation. J Physiology, 590(5), 1311–1324 (2012).
12. Malaguarnera, M. Carnitine improves metabolic flexibility. Clin Pharmacol Adv Appl, 4, 137–149 (2012).
13. Sahlin, K. L-Carnitine and exercise performance. Sports Medicine, 52(1), 45–61 (2022).
Dexpanthenol (Vitamin B5)
14. Said, H. M. Pantothenic acid metabolism and function. Am J Clin Nutr, 111(1), 22–29 (2020).
15. Tsuji, S., et al. Pantothenic acid as Coenzyme A precursor. Biochim Biophys Acta, 1812(2), 147–153 (2011).
16. Vinson, J. A. Vitamin B5 in carbohydrate and lipid metabolism. J Med Food, 18(2), 203–209 (2015).
17. Szentirmai, A. Pantothenic acid deficiency and metabolic impairment. J Nutrition, 67(1), 1–10 (1959).
Lipotropic Injections & Metabolic Blends
18. Miller, G. D. Lipotropic agents in clinical practice. Nutr Clin Practice, 27(1), 50–57 (2012).
19. Friedrich, M., et al. Lipotropic and amino acid injections in metabolic programs. J Obesity Metab Res, 4(3), 137–143 (2017).
20. Galloway, S. D. R., & Broad, E. M. Amino-acid support for weight loss and performance. Sports Medicine, 36(5), 361–378 (2006).
21. Schooneman, M. G., et al. Metabolic flexibility and fatty acid oxidation. J Clin Endocrinol Metab, 98(3), 1136–1146 (2013).
GLP-1 Therapy & Metabolic Adjuncts
22. Samms, R. J., et al. GLP-1 physiology and metabolic adaptation. Nat Rev Endocrinol, 17(3), 153–168 (2021).
23. Lundgren, J. R., et al. Weight loss during GLP-1 agonist therapy. Lancet Diabetes Endocrinol, 9(7), 462–473 (2021).
24. Granhall, C., et al. Nutritional considerations during GLP-1 weight loss. Diabetes Therapy, 11(3), 771–784 (2020).